Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Armelle Dufresne

Showing results (1-10 of 96) with videos related to

Pageof 10
Sort By:
Current Opinion in Oncology|June 17, 2020
Immunotherapy in sarcoma: combinations or single agents? In whom?Armelle Dufresne, Mehdi Brahmi
Current Opinion in Oncology|June 17, 2020
Novel therapeutic options for alveolar soft part sarcoma: antiangiogenic therapy, immunotherapy and beyondMehdi Brahmi, Hélène Vanacker, Armelle Dufresne
Clinical Breast Cancer|May 19, 2007
Efficacy and safety of ixabepilone, a novel epothilone analogueXavier Pivot, Armelle Dufresne, Christian Villanueva
La Revue Du Praticien|January 23, 2026
[Systemic treatment of bone sarcoma, soft tissue sarcoma, GIST]Nathalie Gaspar, Armelle Dufresne, Benjamin Verret
Current Opinion in Oncology|April 30, 2019
Immunotherapy of heterogenous sarcomas: questions and strategiesArmelle Dufresne, Alexandra Meurgey, Mehdi Brahmi
La Revue Du Praticien|June 6, 2008
[Adjuvant chemotherapy for breast cancer and targeted therapies]Armelle Dufresne, Thomas Bachelot, Jean-Yves Blay
Current Opinion in Oncology|May 24, 2023
Treatment of radiation-associated angiosarcomaArmelle Dufresne, Pierre Meeus, Marie-Pierre Sunyach
Bulletin Du Cancer|February 29, 2008
[Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone B analogue]Cristian Villanueva, Armelle Dufresne, Xavier Pivot, et al.
Nature Reviews. Clinical Oncology|April 19, 2018
Using biology to guide the treatment of sarcomas and aggressive connective-tissue tumoursArmelle Dufresne, Mehdi Brahmi, Marie Karanian, et al.
Therapeutics and Clinical Risk Management|August 30, 2008
Trabectedin and its potential in the treatment of soft tissue sarcomaPhilippe A Cassier, Armelle Dufresne, Jean-Yves Blay, et al.
Pageof 10

Showing results (1-10 of 96) with videos related to

Sort By:
Pageof 10
Current Opinion in Oncology|June 17, 2020
Immunotherapy in sarcoma: combinations or single agents? In whom?Armelle Dufresne, Mehdi Brahmi
Current Opinion in Oncology|June 17, 2020
Novel therapeutic options for alveolar soft part sarcoma: antiangiogenic therapy, immunotherapy and beyondMehdi Brahmi, Hélène Vanacker, Armelle Dufresne
Clinical Breast Cancer|May 19, 2007
Efficacy and safety of ixabepilone, a novel epothilone analogueXavier Pivot, Armelle Dufresne, Christian Villanueva
La Revue Du Praticien|January 23, 2026
[Systemic treatment of bone sarcoma, soft tissue sarcoma, GIST]Nathalie Gaspar, Armelle Dufresne, Benjamin Verret
Current Opinion in Oncology|April 30, 2019
Immunotherapy of heterogenous sarcomas: questions and strategiesArmelle Dufresne, Alexandra Meurgey, Mehdi Brahmi
La Revue Du Praticien|June 6, 2008
[Adjuvant chemotherapy for breast cancer and targeted therapies]Armelle Dufresne, Thomas Bachelot, Jean-Yves Blay
Current Opinion in Oncology|May 24, 2023
Treatment of radiation-associated angiosarcomaArmelle Dufresne, Pierre Meeus, Marie-Pierre Sunyach
Bulletin Du Cancer|February 29, 2008
[Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone B analogue]Cristian Villanueva, Armelle Dufresne, Xavier Pivot, et al.
Nature Reviews. Clinical Oncology|April 19, 2018
Using biology to guide the treatment of sarcomas and aggressive connective-tissue tumoursArmelle Dufresne, Mehdi Brahmi, Marie Karanian, et al.
Therapeutics and Clinical Risk Management|August 30, 2008
Trabectedin and its potential in the treatment of soft tissue sarcomaPhilippe A Cassier, Armelle Dufresne, Jean-Yves Blay, et al.
Pageof 10